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Abstract
Hypereosinophilic syndromes (HES) constitute a rare and heterogeneous group of disorders,
defined as persistent and marked blood eosinophilia (> 1.5 × 109/L for more than six consecutive
months) associated with evidence of eosinophil-induced organ damage, where other causes of
hypereosinophilia such as allergic, parasitic, and malignant disorders have been excluded.
Prevalence is unknown. HES occur most frequently in young to middle-aged patients, but may
concern any age group. Male predominance (4–9:1 ratio) has been reported in historic series but
this is likely to reflect the quasi-exclusive male distribution of a sporadic hematopoietic stem cell
mutation found in a recently characterized disease variant. Target-organ damage mediated by
eosinophils is highly variable among patients, with involvement of skin, heart, lungs, and central and
peripheral nervous systems in more than 50% of cases. Other frequently observed complications
include hepato- and/or splenomegaly, eosinophilic gastroenteritis, and coagulation disorders.
Recent advances in underlying pathogenesis have established that hypereosinophilia may be due
either to primitive involvement of myeloid cells, essentially due to occurrence of an interstitial
chromosomal deletion on 4q12 leading to creation of the FIP1L1-PDGFRA fusion gene (F/P+ variant),
or to increased interleukin (IL)-5 production by a clonally expanded T cell population (lymphocytic
variant), most frequently characterized by a CD3-CD4+ phenotype. Diagnosis of HES relies on
observation of persistent and marked hypereosinophilia responsible for target-organ damage, and
exclusion of underlying causes of hypereosinophilia, including allergic and parasitic disorders, solid
and hematological malignancies, Churg-Strauss disease, and HTLV infection. Once these criteria are
fulfilled, further testing for eventual pathogenic classification is warranted using appropriate
cytogenetic and functional approaches. Therapeutic management should be adjusted to disease
severity and eventual detection of pathogenic variants. For F/P+ patients, imatinib has undisputedly
become first line therapy. For others, corticosteroids are generally administered initially, followed
by agents such as hydroxycarbamide, interferon-alpha, and imatinib, for corticosteroid-resistant
cases, as well as for corticosteroid-sparing purposes. Recent data suggest that mepolizumab, an
anti-IL-5 antibody, is an effective corticosteroid-sparing agent for F/P-negative patients. Prognosis
has improved significantly since definition of HES, and currently depends on development of
irreversible heart failure, as well as eventual malignant transformation of myeloid or lymphoid cells.
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Disease name and synonyms
Hypereosinophilic syndromes (HES)
In this article, we have chosen to adopt the classification
scheme proposed by Klion et al., on behalf of the Hypere-
osinophilic Syndromes Working Group that reached a
consensus in Bern in 2005 [1]. Under the umbrella diag-
nosis of "Hypereosinophilic Syndromes", various disease
presentations and pathogenic variants are divided in sub-
groups (see bullets below). This approach offers the
advantage of providing physicians with the full array of
differential diagnosis, once underlying diseases (parasitic,
allergic, neoplastic etc.) classically known to be associated
with hypereosinophilia are excluded by thorough patient
evaluation. It provides a basis for developing a diagnostic
and therapeutic management algorithm of chronic eosi-
nophil-mediated disease.
The following terms are currently used in medical litera-
ture to qualify different patient subsets among those ful-
filling the diagnostic criteria of HES:
• FIP1L1-PDGFRA(F/P)-associated HES, or F/P+ HES, for
patients with clonal hypereosinophilia due to a sporadic
hematopoiëtic stem cell chromosomal rearrangement
resulting in fusion of two genes (FIP1L1 and PDGFRA) on
4q12; these patients are more appropriately classified as
F/P+ chronic eosinophilic leukemia.
• Chronic eosinophilic leukemia (CEL), for patients in
whom clonality of eosinophils has been demonstrated
(including those with the FIP1L1-PDGFRA fusion), or
who present increased blasts; occasional reports indicate
that some patients with CEL progress towards acute mye-
loid or eosinophilic leukemia.
• Lymphocytic-HES (L-HES), for patients with chronic
reactive (polyclonal) hypereosinophilia secondary to IL-5
over-production by T cells.
• Myeloproliferative-HES (M-HES) may be used for
patients with an array of clinical and biological features
suggesting the possible existence of an underlying myelo-
proliferative disorder associated with hypereosinophilia,
although underlying molecular defects are not detected
(including increased serum vitamin B12, hepato- and/or
splenomegaly, anemia and/or thrombocytopenia, circu-
lating myeloid precursors, dysplastic eosinophils, bone
marrow hypercellularity with left shift in maturation,
myelofibrosis, increased serum tryptase, and response to
imatinib); this term is occasionally extended more largely
to include patients with known molecular defects (e.g. F/
P+ CEL or other rare fusions involving the PDGFRA gene)
as well.
• Idiopathic hypereosinophilic syndrome, for patients in
whom underlying pathogenesis remains unknown.
• Organ-restricted eosinophilic disease, such as eosi-
nophilic esophagitis, eosinophilic gastro-enteritis, eosi-
nophilic dermatitis, eosinophilic pneumonia, Kimura's
disease, eosinophilic fasciitis etc., for patients in whom a
specific organ or tissue is the exclusive target of eosi-
nophilic infiltration and damage.
Terms such as disseminated eosinophilic collagen disease
or Löffler's fibroplastic endocarditis with eosinophilia
were used previously to reflect end-organ damage (dis-
seminated or cardiac, respectively) due to direct toxicity of
circulating eosinophils in patients with persistent hypere-
osinophilia, but are currently out-dated.
Definition and diagnostic criteria
The term "hypereosinophilic syndrome" was coined in
1968 to regroup patients with a number of closely related
disorders, all characterized by chronically increased
peripheral blood eosinophil levels, and organ damage
related to eosinophilic infiltration [2]. A working defini-
tion of "idiopathic" HES was proposed by Chusid in
1975: sustained peripheral blood eosinophilia of
unknown origin, exceeding 1.5 × 109/L for more than six
consecutive months, and responsible for the development
of organ dysfunction and/or damage [3]. This definition
was recently extended to include patients with clear-cut
idiopathic hypereosinophilia responsible for end-organ
damage, in whom treatment is initiated rapidly to prevent
further damage, despite non-fulfillment of the duration
criterion. In light of significant advances in understanding
disease pathogenesis in specific patient sub-groups, it has
recently been agreed that the term "idiopathic" be
reserved for HES patients in whom pathogenesis remains
entirely unknown, while the larger umbrella "hypereosi-
nophilic syndrome(s)" be used once again to cover the
heterogeneous disease group characterized by marked
hypereosinophilia accompanied by eosinophilic infiltra-
tion of tissues, encompassing HES variants with well-char-
acterized pathogenic mechanisms, idiopathic HES,
familial HES, and organ-specific eosinophil-mediated dis-
ease (eosinophilic gastro-enteritis, eosinophilic pneumo-
nia ...) (see ref [1] for a recent classification of these
eosinophil-mediated disorders).
Epidemiology
HES is a rare and under-diagnosed disorder, making it dif-
ficult to estimate overall prevalence. To date, there are no
published data on epidemiology of the disease, but an
estimate based on annual hospital discharges (patients
with hypereosinophilia and pertinent co-morbidity) in
the United States, and on United States claims database
for capturing out-patient management, has indicated thatOrphanet Journal of Rare Diseases 2007, 2:37 http://www.OJRD.com/content/2/1/37
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HES could represent approximately a third of chronic
myelogenous leukemia (CML) patients [4]. An improved
approach to HES diagnosis in routine practice and crea-
tion of patient registries are essential steps before a relia-
ble estimation of true prevalence can be made. HES
predominantly affects males, with an estimated male to
female ratio ranging between 4 and 9 to 1 [5]. This is par-
tially explained by the overwhelming majority of males
affected by the F/P+  disease variant, characterized by
occurrence of a sporadic hematopoietic stem cell muta-
tion involving the PDGFRA gene. Disease tends to occur
in patients aged from 20 to 50, but all age groups may be
concerned [5].
Etiology
Eosinophils belong to the myeloid lineage, and differenti-
ate from myeloid progenitors (GEMM-CFU) in bone mar-
row. Among the three cytokines that act as eosinophil
growth factors and apoptosis inhibitors, i.e. granulocyte-
macrophage colony stimulating factor (GM-CSF), IL-3,
and IL-5, only the latter displays specificity for eosi-
nophils [6]. The major source of this eosinophil-specific
cytokine is represented by so-called "type 2" helper T cells
[7]. Recent studies based on material from patients fulfill-
ing Chusid's HES diagnostic criteria have shown that two
distinct underlying mechanisms may lead to chronic
unexplained hypereosinophilia in HES patient subgroups:
occurrence of a sporadic hematopoïetic stem cell muta-
tion, leading to primitive clonal expansion of cells
belonging to the myeloid lineage with preferential eosi-
nophilic differentiation (as such, hypereosinophilia
belongs to the group of chronic myeloproliferative disor-
ders), or overproduction of eosinophilopoietic
cytokine(s) by an activated population of T cells (in the
"lymphocytic variant" of HES, or L-HES) ([for a review see
[8]]).
Until recently, it was difficult to prove eosinophil clonal-
ity and/or to identify a mutation in patients with features
of myeloproliferative disease, and for whom investigators
were convinced an underlying stem cell disorder was
present. In rare cases, some authors were able to show
eosinophil clonality if overt chromosomal abnormalities
were present, and for female patients in whom skewed
methylation patterns of X-linked genes could be demon-
strated in purified eosinophils [9]. Recently, a cryptic
cytogenetic abnormality (which is invisible on routine
karyotypes) has been identified in eosinophils from a sig-
nificant proportion of HES patients, establishing the exist-
ence of a clonal myeloproliferative disorder [10]. Briefly,
an interstitial deletion on chromosome 4q12 results in
fusion of two genes, FIP1L1 and PDGFRA. The new fusion
gene encodes a FIP1LI-PDGFRA (F/P) protein displaying
constitutive tyrosine kinase activity, whose role in disease
induction has been confirmed by its disappearance in
patients successfully treated with the tyrosine kinase
inhibitor, imatinib. Furthermore, the F/P fusion is impli-
cated in malignant transformation of eosinophils/mye-
loid cells, as indicated by its ability to render a murine
hematopoietic cell line independent of growth factors in
vitro following transfection [10], and by its presence in a
cell line derived from a patient with acute eosinophilic
leukemia [10,11]. Although eosinophils are by far the pre-
dominant leukocyte in blood and tissues from patients
with the F/P fusion, this clonal abnormality has been
demonstrated in a number of other cell lineages [12],
including mast cells, which display morphological
changes and which may be the source of increased serum
tryptase levels observed in these patients [13]. The propor-
tion of patients initially fulfilling diagnostic criteria for
HES in whom the F/P mutation is detected varies among
reports, ranging between 17% [14] and 56% [10]. This
variability reflects differences in patient referral to medical
sub-specialties, depending on predominant clinical man-
ifestations and complications of hypereosinophilia.
Experts currently agree that patients with F/P-associated
disease should be classified as chronic eosinophilic leuke-
mia (CEL); however, other terms used in medical litera-
ture include F/P-associated HES or disease, F/P+ HES, or
M-HES. Whether this well-defined patient subgroup
should remain under the umbrella diagnosis of HES or
not remains a controversial issue. From a practical stand-
point, we and others consider that separating disease var-
iants before further progress is made in understanding
pathogenesis of persistent hypereosinophilia, will only
confuse physicians. F/P+ CEL is therefore included in the
overall HES disease spectrum, which in no way interferes
with the formulation of special recommendations regard-
ing diagnosis and management [15].
In L-HES, overproduction of eosinophil growth factors by
T cells leads to increased cycling, differentiation and mat-
uration of eosinophil precursors, as well as prolonged sur-
vival of eosinophils in the periphery, resulting in non-
clonal hypereosinophilia. Interleukin-5-producing T cell
subsets have been described in blood of approximately 35
patients with HES, and a rough estimate would be that at
most one fourth of HES patients present this variant [8].
The allegedly pathogenic T cells display an aberrant sur-
face phenotype in all reported cases, and while CD3-CD4+
cells represent the most frequently encountered subset in
this setting, CD3+CD4-CD8-, CD4+CD7- and other popu-
lations have also been reported [16]. In addition to IL-5,
the CD3-CD4+ cells produce other Th2 cytokines such as
IL-4 and IL-13, as well as GM-CSF. Effects of the Th2
cytokines IL-4 and IL-13 on other cells account for associ-
ated biological features of L-HES. Indeed, B cell stimula-
tion leads to increased IgE synthesis and polyclonal
hypergammaglobulinemia; and effects on antigen pre-
senting cells and/or epithelial cells lead to high-level pro-Orphanet Journal of Rare Diseases 2007, 2:37 http://www.OJRD.com/content/2/1/37
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duction of thymus and activation-regulated chemokine
(TARC), which is increased in serum from such patients
[17]. Clonality of phenotypically aberrant T cells has been
demonstrated in many cases, by analysis of TCR gene rear-
rangement patterns. Clonal cytogenetic abnormalities,
including 16q breakage, partial 6q or 10p deletions [18],
and trisomy 7 have been reported. Although the clonal T
cells are initially benign, several authors have reported
progression towards full-blown T cell lymphoma, indicat-
ing that this initially benign lymphoproliferative disorder
potentially represents a pre-malignant state.
Finally, a good half of patients with HES remain unclassi-
fied, and present truly "idiopathic" hypereosinophilia.
Among these, some present features of myeloproliferative
disease similar to those encountered in F/P+ individuals,
whereas others appear to have more of an "immuno-aller-
gic" disease suggesting possible involvement of T cells.
Further investigation of eosinophils and T cells in these
idiopathic cases, will very likely lead to identification of




The clinical manifestations of HES are variable from one
patient to another, depending on target-organ infiltration
by eosinophils. Organ damage and/or dysfunction devel-
ops as a result of eosinophil release of a number of cyto-
toxic substances, including highly cationic molecules such
as eosinophil cationic protein (ECP) and major basic pro-
tein (MBP), the ribonuclease eosinophil derived neuro-
toxin (EDN), oxydating molecules such as eosinophil
peroxidase (EPO) and free oxygen radicals, and enzymes
such as elastase and collagenase [6]. Eosinophils are also
able to produce lipid mediators, such as leukotrienes and
prostaglandins, which contribute to clinical complica-
tions through effects on vascular and bronchial smooth
muscle tone. Finally, their ability to secrete cytokines
(including pro-inflammatory, Th1 and Th2 cytokines)
and chemokines makes them more sophisticated partici-
pants in the immune response than was once thought
[19]. Eosinophilic inflammation is associated with a pro-
fibrotic environment, as release of TGF-β  by activated
eosinophils leads to increased collagen synthesis and
extracellular matrix deposition. Other mediators of eosi-
nophil-induced tissue remodeling are the subject of
research efforts.
Although virtually any tissue or organ can be affected in
HES, clinical complications arise most frequently (in
more than 50% of patients) in the skin, heart, lungs, and
nervous system [5]:
• Cutaneous manifestations are common and non-spe-
cific, and generally consist either in angioedematous and
urticarial lesions, or erythematous, pruritic papules and
nodules resembling eczema. In patients with L-HES, such
lesions are often the predominant clinical complication of
hypereosinophilia [16,20]. Typical features that compose
Gleich's syndrome, or episodic angioedema with eosi-
nophilia, have been reported in some patients with L-HES
[20-22]. Mucosal ulcerations are possible, especially in
patients with F/P-associated HES [13].
• Cardiac involvement generally evolves in three stages.
The early necrotic stage which involves the endo-myocar-
dium is often asymptomatic, but may present as acute
heart failure in rare instances. This stage is followed by a
thrombotic stage in which thrombi develop along the
damaged endocardium in the cardiac chambers and may
detach, causing peripheral emboli. In the final fibrotic
stage, endomyocardial fibrosis results in irreversible
restrictive cardiomyopathy, and damage to atrioventricu-
lar valves may lead to more acute presentations with con-
gestive heart failure [23]. Endomyocardial fibrosis is the
most pre-occupying non-malignant complication of F/P-
associated disease, as it is generally irreversible [24]. Chest
discomfort, cough, dyspnea or orthopnea, edema of the
lower extremities are typical symptoms reflecting cardiac
involvement, and patients may develop arrhythmias.
• Neurological manifestations may involve both central
(diffuse encephalopathy) and peripheral (polyneuropa-
thy) nervous systems. Diffuse encephalopathy presents as
altered behavior and cognitive function, confusion, and
memory loss. Peripheral neuropathies present as symmet-
ric or asymmetric sensory changes, pure motor deficits, or
mixed sensory and motor complaints. Stroke or transient
ischemic episodes may occur following peripheral embo-
lism of intracardiac thrombi. Thrombosis of intracranial
veins (longitudinal and/or lateral sinus) is a possible
complication of the pro-coagulant state associated with
persistent hypereosinophilia in some patients. To date, no
patients with L-HES have been reported to present neuro-
logical complications, in contrast to F/P+ and idiopathic
patients.
• Lung involvement can range from chronic dry cough
and/or bronchial hyperreactivity in absence of radiologi-
cal abnormalities, to restrictive disease with pulmonary
infiltrates. The latter may occur more frequently in
patients with F/P-associated disease [13]. In rare
instances, development of acute respiratory distress syn-
drome has been reported. Pulmonary fibrosis may
develop after prolonged disease.
• Hematological manifestations include anemia, throm-
bocytopenia, hepatomegaly and splenomegaly, all ofOrphanet Journal of Rare Diseases 2007, 2:37 http://www.OJRD.com/content/2/1/37
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which are more typically encountered in association with
the F/P fusion [13,25]. Mild lymphadenopathy is occa-
sionally observed in patients with L-HES; and appearance
or modification in size of lymph nodes should arouse sus-
picion of T cell lymphoma.
• Coagulation disorders may be observed in HES, and it
is believed that chronic hypereosinophilia may cause
damage to the endovascular surface, accounting for
peripheral vasculopathy, and may also activate coagula-
tion directly. Special attention should be paid to the pres-
ence of nail-fold splint hemorrhages, as peripheral
thromboembolic phenomena may result in occlusion of
terminal vessels in some patients [26] (e.g. digital necro-
sis).
•  Gastrointestinal symptoms may include abdominal
pain, diarrhea, nausea and vomiting. Eosinophilic gastri-
tis, enterocolitis, or colitis may be present, and the latter
may be associated with ascitis if eosinophilic infiltrates
involve deeper layers of the intestinal wall. Such digestive
complications are observed in all forms of HES, including
those with unknown pathogenesis.
• Constitutional symptoms include weakness, fatigue,
anorexia, fever, night sweats, weight loss, arthralgia and
myalgia.
Biological findings
HES patients are also heterogeneous with regard to associ-
ated biological features. Total leukocyte counts can be
normal or increased, and absolute eosinophil numbers
are often well over the defined 1.5 × 109/L. A number of
hematological abnormalities may be observed in periph-
eral blood, especially in F/P+ disease, including presence
of myelocytes, thrombocytopenia or thrombocytosis, and
anemia. Marked increases in serum vitamin B12 levels are
observed in patients with F/P+ disease, and are considered
as indicative of M-HES (i.e. probable myeloproliferative
disorder due to yet unidentified molecular defects),
together with the above-mentioned hematological abnor-
malities and organomegaly [13,25]. High serum immu-
noglobulin E (IgE) levels and polyclonal
hypergammaglobulinemia are more typical of, but not
restricted to, L-HES [20].
Disease course and outcome
Chusid's initial paper and the following published series
clearly illustrated the great clinical heterogeneity and
highly variable prognosis of HES, ranging from pau-
cisymptomatic disease requiring no treatment and associ-
ated with prolonged survival, to rapidly fatal disease
course due to the sudden development of congestive heart
failure or acute leukemia. With the recent distinction of
myelo- versus lympho-proliferative variants, subgroups of
patients with more homogenous clinical profiles can be
defined. Thus, patients with F/P-associated disease often
present heart involvement and mucosal ulcers, and are
overall more likely to develop disease-related morbidity
and mortality [13], whereas patients with L-HES often
present predominant cutaneous manifestations, while
their cardiovascular system is often spared [20]. As for
long-term hematological outcome, patients with F/P-
associated disease are at risk for developing acute leuke-
mia (eosinophilic or myeloid) [25], at times shortly after
diagnosis of HES, while patients with L-HES are at risk of
developing T cell lymphoma, generally after many years of
indolent pre-malignant disease [16,20,27,28].
Although prognosis of HES was very poor when the syn-
drome was first described (88% mortality at 3 years, see
[3]), it has steadily and significantly improved over time
for a number of reasons including earlier detection of
complications, better surgical management of cardiac and
valvular disease, and use of a wider spectrum of therapeu-
tic molecules for controlling hypereosinophilia. Cur-
rently, prognosis depends on two major aspects of
disease: heart involvement and the increased likelihood of
developing hematological malignancies. It is likely that
current and future therapeutic strategies taking patho-
genic disease variants into account will further improve
outlooks for patients with HES in the near future.
Diagnostic methods
Initial work-up of HES requires rigorous step-wise pro-
gression through a diagnostic algorithm. When con-
fronted with a new hypereosinophilic patient, the
physician must first exclude all diseases known to be asso-
ciated with hypereosinophilia before considering diagno-
sis of HES. Secondly, complications of chronic
hypereosinophilia per se must be assessed. And thirdly, an
attempt should be made to determine whether hypereosi-
nophilia arises in the context of a primitive myeloid versus
lymphoid disorder, i.e. to classify patients with regard to
disease variant. The diagnostic procedures (including
patient history and examination, and informative labora-
tory and imaging studies) to exclude underlying diseases
associated with hypereosinophilia (see differential diag-
nosis) will not be detailed in this review.
Organ involvement in HES is highly variable from one
patient to another with regard to its nature and severity. In
a given patient, however, disease flares will often be
accompanied by similar clinical manifestations. Evalua-
tion of complications should obviously be guided by clin-
ical assessment and physical examination, with special
emphasis on the systems known to be targeted by eosi-
nophils: cutaneous, cardiovascular, nervous, respiratory
and digestive systems. Minimal investigations when diag-
nosis of HES is established include an electrocardiogram,Orphanet Journal of Rare Diseases 2007, 2:37 http://www.OJRD.com/content/2/1/37
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echocardiogram, pulmonary function test, and a chest X-
ray. Other imaging studies and/or biopsies should be per-
formed based on clinical findings.
Classification of HES patients remains difficult in a rou-
tine setting, and requires referral of blood and/or marrow
samples to qualified laboratories for optimal evaluation.
Clinically, predominant cutaneous manifestations in
absence of heart involvement, associated with serum
hyperIgE and/or polyclonal hypergammaglobulinemia
should arouse suspicion of L-HES [20]. Likewise,
splenomegaly, heart involvement, mucosal ulcerations,
increased vitamin B12 levels, anemia and/or thrombocy-
topenia, and presence of myeloid precursors in peripheral
blood are indicative of F/P-associated HES [13]. However,
none of these features are entirely specific for a disease
variant, and further testing is warranted for appropriate
categorization and treatment of patients. At the present
time, standard care demands that the three following tests
be performed on peripheral blood and/or bone marrow
for all patients: search for the F/P fusion gene using RT-
PCR (reverse transcription polymerase chain reaction,
preferably nested for increased sensitivity) and/or FISH
(fluorescent in situ hybridisation) for the CHIC2 locus
(absence of this locus is considered a surrogate marker for
presence of the F/P fusion [29]), lymphocyte phenotyp-
ing, and analysis of T cell receptor (TCR) gene rearrange-
ment patterns. Indeed, presence of the F/P fusion clearly
identifies patients with a distinct disease variant that
responds dramatically to treatment with the tyrosine
kinase inhibitor imatinib (see below). On the other hand,
lymphocyte phenotyping in search of a phenotypically
aberrant T cell subset (principally CD3-CD4+, CD3+CD4-
CD8-, and CD4+CD7-), and analysis of TCR gene rear-
rangement patterns using both Southern Blot and PCR
amplification for TCR gene variable regions, in search of T
cell clonality, are generally sufficient to detect patients
with an underlying T cell disorder.
However, despite adherence to the preceding guidelines, a
number of patients will remain unclassified. Additional
investigations in a research setting that may help distin-
guish myeloid and lymphoid disorders include: analysis
of cytokine profiles of T cell subsets including eosinophi-
lopoietic (IL-3 and GM-CSF) and/or type 2 (IL-4, IL-5, IL-
13) cytokines [16,20], measurement of serum tryptase
[13] and TARC levels [17], and cytogenetic analysis focus-
ing on imatinib target tyrosine kinases [30]. There is a gen-
eral consensus among experts in the field that serum or
plasma IL-5 levels are of little value for classification, as
activated eosinophils themselves are able to produce and
secrete this cytokine.
Differential diagnosis
When thorough evaluation of a patient with persistent
hypereosinophilia fails to reveal an underlying disease
known to be associated with increased eosinophil levels,
diagnosis of "HES" can be considered. In the majority of
cases, diagnostic work-up will ultimately lead to diagnosis
of an allergic disorder or parasitosis. Other less frequent
causes of hypereosinophilia include hematological malig-
nancies such as CMML-Eos, Hodgkin's disease and cuta-
neous T cell lymphoma, solid tumors involving the lungs
and colon, systemic vasculitides such as Churg-Strauss
syndrome, connective tissue disease such as rheumatoid
arthritis, infectious disease such as scabies, HIV (human
immunodeficiency virus), HTLV (human T cell lympho-
tropic virus), and allergic bronchopulmonary aspergillo-
sis, skin disease such as psoriasis, endocrine disease such
as adrenal insufficiency, metabolic disease such as choles-
terol embolism, and possible toxicity such as in the his-
toric eosinophilia-myalgia syndrome.
Some hypereosinophilic patients in whom extensive
investigations are negative for underlying diseases present
a characteristic disease pattern in which a given tissue or
organ is specifically targeted by eosinophils. Many of
these idiopathic tissue-specific eosinophil-mediated dis-
orders have been isolated from HES as distinct diseases,
given their tendency to recur only in the initially affected
organ, in absence of other complications of hypereosi-
nophilia. Examples include eosinophilic gastroenteritis,
chronic eosinophilic pneumonia or Carrington's disease,
eosinophilic fasciitis, eosinophilic cellulitis or Wells' syn-
drome, episodic angioedema with eosinophilia or
Gleich's disease, and Kimura's disease. However, whether
a given patient with initially organ-restricted disease will
eventually develop multi-system involvement is impossi-
ble to determine at presentation. For this reason, these
disease presentations have been included in an overlap
category under the umbrella of HES in a recent classifica-
tion [1]. Also, as knowledge on pathogenesis accumulates,
underlying disease mechanisms will over-ride tissue-spe-
cific classifications, as is already the case for patients with
episodic angioedema, some of which present a CD3-CD4+
T cell subset indistinguishable from that found in L-HES
patients with isolated eosinophilic dermatitis (or
eczema).
Treatment
HES are chronic long-standing disorders that develop in
young to middle-aged patients, meaning that therapeutic
options should take long-term toxicity into consideration.
Corticosteroids and hydroxycarbamide have been the cor-
nerstones of management since definition of the syn-
drome in 1975 [5], and interferon alpha (IFN-α) was
introduced in the early 1990s on the basis of several
encouraging studies [31]. A strong need for new therapeu-Orphanet Journal of Rare Diseases 2007, 2:37 http://www.OJRD.com/content/2/1/37
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tic alternatives that specifically target molecular mecha-
nisms underlying hypereosinophilia, while causing as
little unintentional damage as possible, has been voiced
by physicians, given the poor tolerance and numerous
side effects of these compounds. With the recent descrip-
tion of the F/P fusion with constitutive tyrosine kinase
activity in a subgroup of patients, and demonstration of
increased IL-5 production by abnormal T cells in others,
therapeutic perspectives have radically changed in the past
few years.
F/P-associated HES
As mentioned in the paragraph on diagnosis of disease
variants, optimal patient management relies on early test-
ing for the F/P fusion gene. There is general consensus
among experts in the field that patients in whom this
chromosomal rearrangement is detected should be
treated with the tyrosine kinase inhibitor imatinib
(Gleevec®) as first line therapy [1]. A number of clinical
studies showing the striking rapidity and potency of its
effects in this selected patient population have been pub-
lished, and to date, no case of primary resistance to the
molecule has been reported [10,11,24,32]. Response to
therapy in terms of eosinophil levels occurs within days in
most cases, and many clinical manifestations can be
reversed (including dermatitis, mucosal ulcers, restrictive
lung disease, gastrointestinal involvement, central nerv-
ous system manifestations, certain cardiac manifestations,
anemia, thrombocytopenia, and splenomegaly). The dose
required to induce and maintain remission is generally
lower (100 mg/day) than for patients with CML (≥ 400
mg). Influence of imatinib on clinical manifestations
related to HES heart involvement are variable, and some
authors have reported that endomyocardial fibrosis and
related loss of function are not reversible [24,25]. Reversal
of bone marrow pathology and molecular remission, a
major endpoint when dealing with disease mediated by
constitutively activated tyrosine kinases, can be achieved
in most patients with the F/P fusion gene [24,33]. Overall,
imatinib used at doses effective for HES is well tolerated,
as most side effects including edema, muscle pain and
fatigue, are dose-dependent. However, there is some con-
cern regarding adverse effects of imatinib on heart func-
tion. Firstly, a few F/P+  HES patients have developed
severe congestive heart failure within days after initiation
of therapy, and this was felt to be due to massive libera-
tion of toxic eosinophil contents following imatinib-
induced eosinophil death [34,35]. Rapid administration
of corticosteroids has proven effective in handling this
preoccupying complication [34]. Authors have suggested
that heart function be monitored closely prior to and at
the beginning of treatment, and serial measurements of
cardiac troponin T be performed to predict this poten-
tially fatal adverse event. Patients with increased levels
prior to therapy should be treated preventively with corti-
costeroids a few days before initiating imatinib. Secondly,
a recent study investigating cardiomyocytes from CML
patients treated with imatinib (generally used at higher
doses than for HES patients) and subsequently develop-
ing left ventricular dysfunction (after a mean of 7.2
months of treatment), has shown presence of membrane
whorls and pleomorphic mitochondria with effaced cris-
tae [36]. The mechanisms underlying imatinib-induced
myocyte toxicity were investigated in mice, in which mito-
chondria were also identified as the chief target of this
compound. Energy rundown due to mitochondrial dys-
function was shown to be responsible for cardiotoxicity.
Relapse of hypereosinophilia during treatment with imat-
inib has been reported in two F/P+ patients, and was asso-
ciated with appearance of a T674I point mutation in the
ATP-binding site of the PDGFRA moiety, similar to the
T315I mutation observed in patients with CML that
become refractory to treatment [10,37]. It has been rec-
ommended that the dose of imatinib used for patients
with F/P+ HES should be adjusted to ensure molecular
remission, in order to decrease the risk of acquired resist-
ance to treatment [1]. Several alternative tyrosine kinase
inhibitors have been tested in vitro and in vivo (murine
model of F/P-associated disease) for effects on F/P activity.
One molecule, nilotinib (AMN107), is able to inhibit
kinase activity of wild-type F/P [38]. Two other com-
pounds, PKC412 which is structurally unrelated to imat-
inib [39], and sorafenib [40], are able to inhibit kinase
activity of both wild-type F/P and its imatinib -resistant
T674I mutant form.
Although imatinib has clearly become first-line therapy
for patients with F/P-associated disease, overall follow-up
of treated patients is short, and a number of questions
remain unanswered. Namely, it is currently unclear
whether imatinib can be curative for HES, through perma-
nent eradication of the leukemic F/P+  clone. Several
reports have shown that interruption of imatinib in F/P+
patients in molecular remission, is followed by recurrence
of the molecular defect within months [33,41].
F/P-negative HES
To date, no general consensus has been reached on the
ideal treatment algorithm for HES patients without the F/
P fusion. In general, corticosteroids are administered as
first line therapy, starting with a dose of 1 mg/kg/d or 60
mg prednisone. If a response is observed, prednisone is
carefully tapered to the lowest possible dose that main-
tains eosinophil counts and/or clinical manifestations
under control, defining the level of corticosteroid-
dependency. Depending on the dose of corticosteroids
required and on patient tolerance, physicians frequently
attempt to further reduce the dose by introducing a corti-
costeroid-sparing agent. If no response to corticosteroidsOrphanet Journal of Rare Diseases 2007, 2:37 http://www.OJRD.com/content/2/1/37
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is observed (i.e. corticosteroid-resistance), second-line
therapy is warranted.
Compounds that are used for corticosteroid-sparing and
for second-line purposes include hydroxycarbamide, IFN-
α and imatinib. Recent studies indicate that monoclonal
anti-IL-5 antibodies may represent an interesting thera-
peutic alternative. Other compounds such as ciclosporin,
vincristine, and anti-CD52 antibodies (alemtuzumab)
have proven useful in some patients. Available data on
administration of cytotoxic molecules such as cyclophos-
phamide, methotrexate, busulfan, and chlorambucil, are
not that encouraging and there are currently no recom-
mendations in favor of their use in HES. Choice of which
agent to use in a given patient is up to the clinician, and
the following paragraphs review briefly the characteristics
of available alternatives.
Hydroxycarbamide has been used extensively for treating
HES, generally at doses between 1 and 2 g/d [1,5]. The
effect of hydroxycarbamide on eosinophilia is central,
meaning that reduction of eosinophil levels is not to be
expected before two weeks after initiation of therapy.
Adverse events are frequently observed, including hema-
tological toxicity and gastrointestinal intolerance. Pub-
lished reports on successful treatment of HES with
hydroxycarbamide lack detailed clinical and diagnostic
information that would allow speculations on which dis-
ease variants could benefit from therapy. Theoretically,
this compound would appear more useful for treating
patients with myeloproliferative features; however, it
effectively lowered eosinophil levels in one patient with a
CD3-CD4+  clone. Some investigators have combined
hydroxycarbamide and IFN-α in order to lower individual
doses of each compound, thereby increasing overall toler-
ance [42].
Interferon-α has also been used successfully for manage-
ment of HES [31]. Although highly variable dosing regi-
mens have been used, it appears that doses of 1–2 million
units/d are often sufficient to control eosinophil levels. It
may take weeks before a response is observed, meaning
that it may take months before a stable effective dose is
reached. Common side effects include flu-like symptoms
that tend to improve over time, depression, fatigue, and
increased liver transaminases. Many IFN-α  responders
reported in the literature present a number of features sug-
gestive of myeloproliferative disease, but these reports
pre-date description of F/P-associated disease and L-HES.
A corticosteroid-sparing effect of IFN-α has been observed
in two of our patients with CD3-CD4+ clones, which could
be related to inhibition of IL-5 production [43] and anti-
proliferative effects. However, these encouraging results
are challenged by the observation that IFN-α  prolongs
survival of clonal CD3-CD4+ cells in vitro by inhibiting
spontaneous apoptosis, and may therefore provide these
cells with a selective advantage [44]. Given the malignant
potential of aberrant T cells associated with L-HES, we
would recommend avoidance of IFN-α as monotherapy
in this setting, and prefer combining with corticosteroids.
In F/P-negative HES patients, the place of imatinib among
therapeutic options has not yet been defined. Several
investigators have reported responses to imatinib in a var-
iable proportion of such patients, suggesting that an uni-
dentified cytogenetic rearrangement leads to acquisition
of imatinib-sensitive autonomous tyrosine kinase activity.
To date, there is no data available on potential biomarkers
that would help identify F/P-negative patients with imat-
inib-sensitive disease. A short course of imatinib 400 mg
daily could be proposed to patients with clinical and bio-
logical findings typically encountered in myeloprolifera-
tive disease (see those listed above for "M-HES") and
those resistant to therapy with corticosteroids; rapid evi-
dence of a hematological response would be encouraging
for treatment prolongation. In a recent review of 94 pub-
lished cases of HES treated with imatinib, it was suggested
that presence of splenomegaly or lung disease could be
associated with a higher probability (89% and 96%
respectively) of complete hematological response to imat-
inib [45]. In contrast to patients with F/P-associated dis-
ease, response of F/P-negative patients to imatinib is
variable, and may only be transient in some cases, or may
require higher doses.
The recent development of humanized anti-IL-5 mAbs,
designed to target eosinophils in allergic disorders by
interfering with ligation of IL-5 to the α -chain of the IL-
5R on their surface, has raised considerable interest
among investigators dealing with HES [46]. There is
strong scientific rationale for treatment of HES patients
with anti-IL-5 mAb, given the specificity of this cytokine
for the eosinophil lineage, and the assumption that tissue
damage in HES is directly related to presence of activated
eosinophils. Initially, two molecules were developed for
intravenous use (mepolizumab by GlaxoSmithKline and
formerly SCH55700 by Schering Plough) and tested in
HES patients, some of whom were corticosteroid non-
responders, in the setting of compassionate use programs.
Encouraging results were reported, with a rapid decline of
blood eosinophil counts shortly after administration in
most patients [47-49]. This was associated with decreased
eosinophil degranulation, reflected by reduced serum
eosinophil cationic protein (ECP) levels [47]. In most
cases, successful eosinophil depletion in blood was asso-
ciated with improvement of a wide spectrum of clinical
manifestations (including rash, angioedema, mucosal
ulcers, myalgia, arthralgia, dysphagia, vomiting, nasal
congestion and polyposis), correlating with significant
reductions of eosinophil numbers in the skin and esopha-Orphanet Journal of Rare Diseases 2007, 2:37 http://www.OJRD.com/content/2/1/37
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gus of patients with eosinophilic dermatitis [47] and
severe eosinophilic esophagitis [48], respectively. Among
patients under corticosteroids before treatment initiation,
several could be tapered down or off after mepolizumab
infusions, supporting its use as a corticosteroid-sparing
agent in HES. Eosinophil depletion and clinical remission
following administration of 750 mg mepolizumab
appears to last weeks or even months in some cases, and
two patients with eosinophilic dermatitis have experi-
enced persistent remission (with follow-up of 17 months
in one case) following treatment discontinuation [47].
These individual compassionate case studies have sug-
gested that HES patients with various profiles could bene-
fit from treatment with anti-IL-5, including corticosteroid-
responders and non-responders, and patients with both
myeloproliferative (including one patient in whom the F/
P fusion gene was later demonstrated [49]) and possible T
cell mediated disease [47].
Although SCH55700 is no longer available, mepolizu-
mab has recently been administered to a large number of
F/P-negative corticosteroid-responsive HES patients in the
setting of an international multicentric, randomized, dou-
ble-blind, placebo-controlled clinical trial (750 mg
administered intravenously every 4 weeks) [50]. This
study has shown that mepolizumab allows effective corti-
costeroid-sparing compared to placebo, while maintain-
ing disease control, and is well tolerated. An open-label
extension study is currently on-going, addressing the opti-
mal dosing interval between mepolizumab infusions, as
well as long-term side effects associated with treatment
itself and prolonged eosinopenia. Hopefully, additional
analysis will identify biomarkers predictive of response to
therapy with anti-IL-5.
Although anti-IL-5 mAbs display an excellent safety pro-
file with minimal if any reported side effects, some con-
cern regarding rebound hypereosinophilia between
infusions or after cessation of therapy has been raised.
One study using SCH55700 at low doses (1 mg/kg) has
shown that serum IL-5 levels actually increased during
treatment, and this appeared not to be related to increased
IL-5 production by peripheral blood leukocytes [49];
mechanisms underlying IL-5 over-production or
decreased IL-5 clearance during therapy remain to be clar-
ified. Whether a similar phenomenon occurs with mepoli-
zumab, remains unknown, and will be evaluated in the
setting of the above-mentioned clinical trials.
An interesting therapeutic target in patients with L-HES is
the CD52 antigen, which is expressed both on T cells and
eosinophils. In a recent report, alemtuzumab, a mono-
clonal anti-CD52 antibody, was shown to be effective
treatment for a patient with a CD3-CD4+ T cell subset,
inducing rapid normalization of eosinophil levels and
clinical remission [51].
Ciclosporin interferes with calcium-mediated intracellu-
lar signaling pathways and inhibits nuclear translocation
of the transcription factor NF-AT, which is essential for a
number of T cell functions including cytokine synthesis.
Ciclosporin is classically used for treating auto-immune
disorders, by targeting T cells. A few authors have reported
successful use of ciclosporin as a corticosteroid-sparing
agent in a limited number of HES patients [52]. Given the
pathogenic role of T cells in L-HES, and dependence of
CD3-CD4+ T cells on IL-2 for proliferation and cytokine
production [53], ciclosporin or other agents interfering
with IL-2/IL-2R interactions, may theoretically be useful
for this HES variant. This remains entirely to be assessed.
Vincristine is a cytotoxic agent that is rarely used for man-
agement of HES. It may prove useful for rapidly lowering
eosinophilia in patients with extremely high eosinophil
counts (> 100 × 109/L), and has been proposed in some
pediatric cases that are refractory to classical therapeutic
regimens [1]. The recommended dose for adults is 1–2 mg
intravenously.
Finally, HES patients that are refractory to classical ther-
apy and who present progressive life-threatening end-
organ damage may be candidates for allogeneic stem cell
transplantation (SCT), whether they test positive for the F/
P fusion or not. Obviously, this strategy requires careful
thought given the inherent morbidity and mortality
related to the procedure. Potential indications for SCT
may include patients with F/P-associated disease who are
intolerant to or no longer respond to imatinib [1], and
patients initially presenting L-HES who develop periph-
eral T cell lymphoma, as eradication of malignant T cells
is not easily achieved using classical chemotherapeutic
regimens.
Overall, management of patients with HES has improved
significantly, especially since the rapid initiation of imat-
inib in patients with F/P+ disease. As for L-HES, there is
now increased awareness that despite the clinically
"benign" presentation with relative sparing of end-organs,
patients should be closely monitored for development of
T cell malignancy. However, the molecular picture of L-
HES remains uncomplete and specific molecular targets
for therapy have not been identified, meaning that in the
meantime therapy relies largely on corticosteroids, with
eventual addition of corticosteroid-sparing agents such as
IFN-α. Interesting options for future investigation may
include alemtuzumab, extracorporeal photopheresis, and
efalizumab (J. Huss-Marp, personal observation).Orphanet Journal of Rare Diseases 2007, 2:37 http://www.OJRD.com/content/2/1/37
Page 10 of 12
(page number not for citation purposes)
Unresolved questions
• Striking male predominance of F/P-associated hypere-
osinophilic disease.
• Identification of underlying hematological abnormality
in patients in whom diagnostic work-up fails to demon-
strate eosinophil clonality (for example F/P fusion gene)
or T cell populations producing eosinophilopoietic
cytokines (L-HES). This includes characterization of the
underlying tyrosine kinase abnormality in patients
responding to imatinib, and lacking the F/P mutation.
• Long-term effects of imatinib on natural disease course
of F/P-associated disease (i.e. ability or not to prevent
blastic transformation, occurrence of imatinib-resist-
ance).
• Role of the CD3-negative phenotype of pathogenic T
cells underlying L-HES in malignant progression towards
lymphoma.
• Identification of T cell molecular targets in patients with
L-HES, for development of specific disease-modifying
therapeutic strategies.
Abbreviations
cGVHD chronic graft versus host disease
CEL chronic eosinophilic leukemia
CMML-Eos chronic myelo-monocytic leukemia with eosi-
nophilia
ECP eosinophil cationic protein
EPO eosinophil peroxydase
FIP1L1 FIP1 (gene derived from Saccharomyces Cervisiae)
like 1
F/P FIP1L1-PDGFRA fusion
GM-CSF granulocyte macrophage colony stimulating fac-
tor
HES hypereosinophilic syndrome
HIV human immunodeficiency virus
HTLV human T cell lymphotropic virus
IFN-α interferon alpha
IL interleukin
MBP major basic protein
PCR polymerase chain reaction
PDGFRA platelet derived growth factor receptor alpha
TCR T cell receptor
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